Cipla Ltd vs Pharmaids Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Cipla Ltd is ₹ 1295 as of 12 May 16:01 . The P/E Ratio of Cipla Ltd changed from 27.3 on March 2021 to 22.1 on March 2025 . This represents a CAGR of -4.14% over 5 yearsThe P/E Ratio of Pharmaids Pharmaceuticals Ltd changed from 89.4 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Cipla Ltd changed from ₹ 65746 crore on March 2021 to ₹ 116434 crore on March 2025 . This represents a CAGR of 12.11% over 5 yearsThe Market Cap of Pharmaids Pharmaceuticals Ltd changed from ₹ 12.9 crore on March 2022 to ₹ 242.18 crore on March 2025 . This represents a CAGR of 108.16% over 4 years The revenue of Cipla Ltd for the Dec '25 is ₹ 7280 crore as compare to the Sep '25 revenue of ₹ 7858 crore. This represent the decline of -7.35% The revenue of Pharmaids Pharmaceuticals Ltd for the Dec '25 is ₹ 5.51 crore as compare to the Sep '25 revenue of ₹ 11.63 crore. This represent the decline of -52.62% The ebitda of Cipla Ltd for the Dec '25 is ₹ 1185 crore as compare to the Sep '25 ebitda of ₹ 2163 crore. This represent the decline of -45.21% The ebitda of Pharmaids Pharmaceuticals Ltd for the Dec '25 is ₹ -2.83 crore as compare to the Sep '25 ebitda of ₹ -2.3 crore. This represent the growth of 23.04% The net profit of Cipla Ltd changed from ₹ 1176 crore to ₹ 674.56 crore over 7 quarters. This represents a CAGR of -27.22% The net profit of Pharmaids Pharmaceuticals Ltd changed from ₹ -3.12 crore to ₹ -2.65 crore over 7 quarters. This represents a CAGR of -8.91% The Dividend Payout of Cipla Ltd changed from 16.34 % on March 2021 to 25.05 % on March 2025 . This represents a CAGR of 8.92% over 5 yearsThe Dividend Payout of Pharmaids Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Cipla Ltd

Cipla Limited is one of the leading pharmaceutical companies in India.
The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Limited, incorporated in March, 1989 at Hyderabad, Telangana were suppliers of Quality Grade range of speciality chemicals, skin care, hospital care and generic products in the areas of Orthopedic, Neuro and Gastro etc.
The technical team used quality proven chemical compounds and standard processing methods maintaining proper hygiene standards.The Company is engaged in the business of contract research and manufacturing services. Emergent Bio Naturals Limited (EBNL) was amalgamated with the Company in 2019-20 and the Scheme of Amalgamation was effective on September 27, 2019.
Pursuant to the Scheme, 69,05,734 Equity Shares were allotted to Shareholders of Emergent Bio Naturals Limited on November 27, 2019. The Company acquired 25.5% stake as 1st tranche in Anugraha Chemicals, a Partnership Firm, registered under Karnataka Partnership Rules, 1954 on February 1, 2023.

FAQs for the comparison of Cipla Ltd and Pharmaids Pharmaceuticals Ltd

Which company has a larger market capitalization, Cipla Ltd or Pharmaids Pharmaceuticals Ltd?

Market cap of Cipla Ltd is 105,391 Cr while Market cap of Pharmaids Pharmaceuticals Ltd is 109 Cr

What are the key factors driving the stock performance of Cipla Ltd and Pharmaids Pharmaceuticals Ltd?

The stock performance of Cipla Ltd and Pharmaids Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Pharmaids Pharmaceuticals Ltd?

As of May 12, 2026, the Cipla Ltd stock price is INR ₹1304.7. On the other hand, Pharmaids Pharmaceuticals Ltd stock price is INR ₹31.18.

How do dividend payouts of Cipla Ltd and Pharmaids Pharmaceuticals Ltd compare?

To compare the dividend payouts of Cipla Ltd and Pharmaids Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.